Modus Therapeutics: SEVUSMART study of sevuparin in children with severe malaria published in Nature Communications

Wait 5 sec.

Modus Therapeutics Holding AB (publ) announces that the manuscript based on the Phase Ib study SEVUSMART in severe malaria, lead-authored by Professor Kathryn Maitland of Imperial College London with co-authors from the SMAART consortium including members such as University College London and the University of Oxford, has been published today in the peer-reviewed journal Nature Communications, following independent peer review.